Saxagliptin

Details

Files

Generic Name:

Saxagliptin

Project Status:

Complete

Therapeutic Area:

Diabetes mellitus, type 2

Manufacturer:

Bristol-Myers Squibb / AstraZeneca Canada Inc.

Call for patient/clinician input open:

May 9, 2013

Brand Name:

Onglyza

Project Line:

Reimbursement Review

Project Number:

SR0329-000

Call for patient/clinician input closed:

May 31, 2013

NOC Status at Filing:

Pre NOC

Performance Metric:

N/A — Predated performance metrics

Submission Type:

Initial

Indications:

Diabetes mellitus (Type 2)

Recommendation Type:

List with criteria/condition

Final Recommendation:

November 15, 2013

Files

Recommendation and Reasons: Updated View PDF

Submission Status Report View PDF

Recommendation and Reasons: Original View PDF

Clinical Report View PDF

Pharmacoeconomic Report View PDF

Last Updated : March 22, 2024